Earn points on every order · Free shipping on orders over $159 · New products in stock
← Back to Compound Library
Fat Loss and Metabolism

DULAGLUTIDE

An FDA-approved once-weekly GLP-1 (brand Trulicity), used for type-2 diabetes and weight management. Same appetite-curbing, blood-sugar-lowering family as semaglutide, with simple weekly dosing.

Research referenceCommunity compiled
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

An FDA-approved once-weekly GLP-1 (brand Trulicity), used for type-2 diabetes and weight management.

Same appetite-curbing, blood-sugar-lowering family as semaglutide, with simple weekly dosing.

What It Does

Dulaglutide is a long-acting GLP-1 receptor agonist (an antibody-Fc fusion).

It enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite.

FDA-approved (Trulicity) for type-2 diabetes; produces moderate weight loss.

Once-weekly.

Reconstitution

Vial SizeBAC Water / SolventConcentration
5 mg+ 1 mL5 mg/mL
10 mg+ 2 mL5 mg/mL
Interactive tool

Reconstitution Calculator

Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.

Calculated concentration—Enter both values above.
Optional conversion

Enter a target amount you already have and select the syringe capacity.

Calculated draw—Enter concentration inputs and a target amount.

Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.

Protocol

PhaseFrequencyAmountNotes
Weeks 1–4Once weekly0.75 mgStarting dose (FDA Trulicity).
Weeks 5–8Once weekly1.5 mgStep up if tolerated.
Weeks 9–12Once weekly3.0 mg
Week 13+Once weekly4.5 mgMax labeled dose.
Cycle & Timing

escalate every 4 weeks as tolerated to the 4.5 mg max. Continuous use is standard for the indication.

Timing

same day each week, any time, with or without food. FDA: approved as Trulicity for type-2 diabetes; weight loss is moderate vs semaglutide/tirzepatide.

Population Considerations

Women lose more than men at the same dose but report more GI (start lower). In PCOS they improve cycles, lower free testosterone and raise ovulation; a real unplanned-pregnancy risk. Stop before conceiving. Men: In men, excess fat lowers testosterone; GLP-1 raises total testosterone, SHBG and gonadotropins as weight drops, and improves sperm and erectile function; and preserves fertility, unlike TRT (which suppresses spe Women lose more than men at the same dose but report more GI (start lower). In PCOS they improve cycles, lower free testosterone and raise ovulation; a real unplanned-pregnancy risk. Stop before conceiving. Men: In men, excess fat lowers testosterone; GLP-1 raises total testosterone, SHBG and gonadotropins as weight drops, and improves sperm and erectile function; and preserves fertility, unlike TRT (which suppresses sperm).

Handling & Stacking

Injection site
SubQ, abdomen/thigh/upper arm. Rotate.
Storage
  • Freeze-dried: -4°F.
  • Reconstituted: 36–46°F.
  • Best used within 28 days.
  • No clear reconstituted-potency data (the pen label gives an in-use date, not potency), so defer to the 28-day sterility limit. (Commercial Trulicity is pre-filled, refrigerated.)
Side effects
Nausea, diarrhea, vomiting, reduced appetite, injection-site reactions. GI effects dose-dependent.
What to expect
Lower blood sugar and appetite within weeks; moderate weight loss over months. Supply math 5mg → 10 vials | 10mg → 5 vials (12-wk titration to 4.5 mg/wk)
Pairs well with
Lipo-C / L-Carnitine (metabolic support). Do not combine with other GLP-1 / incretin agents
Avoid
Personal/family history of medullary thyroid carcinoma or MEN2. Prior pancreatitis. Pregnancy. Other GLP-1s

Safety & Patient Education

Contraindications
Personal/family history of medullary thyroid carcinoma or MEN2 (boxed warning) Prior pancreatitis Pregnancy and lactation Type 1 diabetes / diabetic ketoacidosis
Warnings
Thyroid C-cell tumors in rodents (boxed warning) Gallbladder disease with rapid weight loss Hypoglycemia when combined with insulin/sulfonylureas Diabetic retinopathy complications with rapid glucose improvement Acute kidney injury from dehydration (vomiting/diarrhea)
Drug interactions
Insulin / sulfonylureas: reduce dose to avoid hypoglycemia Delayed gastric emptying alters oral drug absorption Other GLP-1 agents: do not combine
Labs
  • Fasting glucose / HbA1c (baseline + periodic) Renal function with significant GI losses Lipase if pancreatitis suspected Resting heart rate (GLP-1s nudge it up a few bpm) Out of range?
  • Rising glucose/HbA1c = blood sugar creeping toward diabetes (recheck, tighten diet); a falling eGFR = kidney strain, usually dehydration (hydrate, hold the dose).
Stop criteria
Severe persistent abdominal pain (pancreatitis) Persistent vomiting / dehydration Signs of gallbladder disease (RUQ pain, jaundice) Pregnancy
Patient education
FDA-approved GLP-1, same class precautions as semaglutide Titrate every 4 weeks; most nausea is early and improves Hydrate and maintain protein intake Stop and seek care for severe abdominal pain or persistent vomiting
References
rxlist · dailymed · researchdosing · peptidedosages · GLP-1 sex differences · Jensterle 2020